LTGO Stock — Latigo Biotherapeutics Inc.: Cash, EV, Pipeline

Share price

$22.55

Market cap

$1,495.1M

Cash

$370.7M

Enterprise value

$1,124.4M

Balance sheet

Cash	$370.7M
Debt	$0.0M
Net cash	$370.7M
Enterprise value	$1,124.4M
Basic shares	1.0M shares
Fully diluted shares	118.4M shares
Fully diluted market cap	$2,670.4M
Cash per share	$370.70

Cash figures as of 2026-08-10. Database snapshot: 2026-09-21.

Price history

Loading LTGO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	LTG-001	Phase 1	Healthy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Onzotrigine

Phase 2 · Active Modality: small molecule (oral; IV formulation also in development)

Target Nav1.8 (voltage-gated sodium channel)

Partnerships Lieber Institute: worldwide license agreement (2020, amended 2020 and 2022)

Indications

moderate to severe acute pain (incl. postoperative) (Phase 2)

Catalysts

— second half of 2026
— second half of 2027

Status note Lead candidate: oral Nav1.8 inhibitor for acute pain. Completed pivotal-design abdominoplasty trial met primary and key secondary endpoints; NDA requires a Phase 3 program plus open-label safety trial. IV formulation in development for hospital use.

LTG-321

Phase 2 · Active Modality: small molecule (oral)

Target Nav1.8 (voltage-gated sodium channel)

Indications

chronic musculoskeletal pain (starting with knee osteoarthritis) (Phase 2)

Catalysts

— second half of 2027

Status note Next-generation Nav1.8 inhibitor, structurally distinct from onzotrigine, designed for chronic use (lower effective dose, potential once-daily). Phase 2 proof-of-concept crossover trial in knee OA (~120 patients) initiated.

LTG-418

Preclinical · Active Modality: small molecule

Target Nav1.8 (voltage-gated sodium channel)

Indications

acute and chronic pain (Preclinical)

Status note Next-generation Nav1.8 inhibitor, structurally distinct from onzotrigine and LTG-321, predicted to have a substantially lower dose; non-GLP 14-day toxicology completed in rats and non-human primates. Additional earlier-stage Nav1.8 programs undescribed as distinct candidates.

Per-asset detail extracted from the 10-Q filed 2026-09-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	LTG-001
Lead indication	Healthy
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06049095	Phase 1	Active, not recruiting	Sponsor	Latigo Biotherapeutics	—	Healthy	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Latigo Biotherapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

LTGO — Latigo Biotherapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials